Quanterix Co. (NASDAQ:QTRX - Get Free Report) Director David R. Walt bought 36,010 shares of Quanterix stock in a transaction that occurred on Thursday, June 12th. The stock was bought at an average price of $6.23 per share, for a total transaction of $224,342.30. Following the completion of the acquisition, the director now directly owns 1,742,943 shares of the company's stock, valued at $10,858,534.89. The trade was a 2.11% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.
Quanterix Price Performance
Shares of NASDAQ:QTRX traded down $0.13 during mid-day trading on Friday, hitting $6.06. The company had a trading volume of 567,189 shares, compared to its average volume of 591,459. Quanterix Co. has a one year low of $4.05 and a one year high of $18.02. The firm has a fifty day moving average price of $5.32 and a 200 day moving average price of $7.81. The company has a market capitalization of $235.30 million, a PE ratio of -5.72 and a beta of 1.05.
Quanterix (NASDAQ:QTRX - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.16. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. The firm had revenue of $30.33 million during the quarter, compared to the consensus estimate of $28.27 million. Research analysts expect that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.
Institutional Trading of Quanterix
Several large investors have recently made changes to their positions in QTRX. Jane Street Group LLC raised its stake in Quanterix by 4.2% during the 1st quarter. Jane Street Group LLC now owns 58,313 shares of the company's stock worth $380,000 after buying an additional 2,366 shares during the period. SCS Capital Management LLC bought a new stake in shares of Quanterix during the first quarter valued at approximately $2,307,000. Goldman Sachs Group Inc. raised its position in shares of Quanterix by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 349,696 shares of the company's stock worth $2,277,000 after purchasing an additional 59,655 shares during the period. Invenomic Capital Management LP acquired a new position in shares of Quanterix during the first quarter worth approximately $5,872,000. Finally, AQR Capital Management LLC lifted its holdings in shares of Quanterix by 204.4% in the 1st quarter. AQR Capital Management LLC now owns 98,990 shares of the company's stock worth $644,000 after purchasing an additional 66,470 shares in the last quarter. 86.48% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on QTRX. Canaccord Genuity Group dropped their price target on shares of Quanterix from $15.00 to $12.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Leerink Partnrs downgraded shares of Quanterix from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Leerink Partners reaffirmed a "market perform" rating and set a $8.00 price target (down previously from $12.00) on shares of Quanterix in a research report on Wednesday, April 30th. Wall Street Zen downgraded Quanterix from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Finally, Scotiabank reissued an "outperform" rating on shares of Quanterix in a research report on Tuesday, March 25th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $15.60.
Read Our Latest Stock Analysis on QTRX
About Quanterix
(
Get Free Report)
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Quanterix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quanterix wasn't on the list.
While Quanterix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
